- Home
- CNX vs AXSM Comparison
CNX vs AXSM Comparison
Compare CNX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNX | AXSM |
|---|---|---|
| Founded | 1860 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 7.4B |
| IPO Year | 1999 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CNX | AXSM |
|---|---|---|
| Price | $36.62 | $152.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | $34.50 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 2.1M | 464.4K |
| Earning Date | 01-29-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $1,930,542,000.00 | $561,263,000.00 |
| Revenue This Year | $49.64 | $66.40 |
| Revenue Next Year | $2.18 | $56.13 |
| P/E Ratio | $18.15 | ★ N/A |
| Revenue Growth | 40.99 | ★ 65.83 |
| 52 Week Low | $27.00 | $75.56 |
| 52 Week High | $42.13 | $158.57 |
Technical Indicators
Market Signals| Indicator | CNX | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 58.25 |
| Support Level | $36.84 | $152.41 |
| Resistance Level | $37.99 | $158.56 |
| Average True Range (ATR) | 1.18 | 4.13 |
| MACD | -0.49 | 0.08 |
| Stochastic Oscillator | 1.75 | 55.41 |
Price Performance
Historical ComparisonAbout CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.